National Early Warning Score 2 and laboratory predictors correlate with clinical deterioration in hospitalized patients with COVID-19

Gulsah Tuncer1, Serkan Surme*,1, Osman F Bayramlar2, Hatice K Karanalbant1, Betul Copur1, Meltem Yazl1, Esra Zerdali1, Inci Y Nakir1, Ayse RK Cinari1, Ahmet Buyukyazgan1, Hatice Balli1, Yesim Kurekci1, Serap Simsek-Yavuz2, Mehmet M Sonmez2, Gonul Sengoz1 & Filiz Pehlivanoglu1

1Department of Infectious Diseases & Clinical Microbiology, Haseki Training & Research Hospital, Istanbul, Turkey
2Department of Public Health, Bakirkoy District Health Directorate, Istanbul, Turkey
3Department of Infectious Diseases & Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
4Department of Orthopaedic Surgery & Traumatology, Haseki Training & Research Hospital, Istanbul, Turkey

*Author for correspondence: Tel.: +90 555 857 8517; serkansurme@hotmail.com

Aim: We aimed to determine the prognostic values of the National Early Warning Score 2 (NEWS2) and laboratory parameters during the first week of COVID-19. Materials & methods: All adult patients who were hospitalized for confirmed COVID-19 between 11 March and 11 May 2020 were retrospectively included. Results: Overall, 611 patients were included. Our results showed that NEWS2, procalcitonin, neutrophil/lymphocyte ratio and albumin at D0, D3, D5 and D7 were the best predictors for clinical deterioration defined as a composite of ICU admission during hospitalization or in-hospital death. Procalcitonin had the highest odds ratio for clinical deterioration on all days. Conclusion: This study provides a list of several laboratory parameters correlated with NEWS2 and potential predictors for clinical deterioration in patients with COVID-19.

Lay abstract: The COVID-19 pandemic is a grueling problem worldwide. There is a lack of knowledge about the predictive value of National Early Warning Score 2 (NEWS2) for severe COVID-19 illness. We analyzed the prognostic value of NEWS2 and laboratory parameters during the clinical course of COVID-19. This study provides a list of several laboratory parameters correlated with NEWS2 and potential predictors for intensive care unit admission during hospitalization or in-hospital death.

First draft submitted: 23 January 2021; Accepted for publication: 23 March 2021; Published online: 21 July 2021

Keywords: albumin • COVID-19 • in-hospital mortality • neutrophil/lymphocyte ratio • NEWS2 • procalcitonin

The COVID-19 pandemic due to the SARS-CoV-2 virus causes high rates of mortality, morbidity, longer duration of hospitalization and increased need for intensive care unit (ICU) admission [1]. Improving critical care patient flow is crucial for high-quality care in severe cases. Therefore, we need to predict clinical deterioration in patients with COVID-19, in order to hospitalize the patients and admit to ICU, when necessary. The National Institute for Health and Care Excellence recommend the National Early Warning Score 2 (NEWS2) to predict the risk for clinical deterioration in patients with COVID-19 [2,3]. NEWS2 is a simple scoring system including physiological parameters and vital signs (respiratory rate, oxygen saturation, systolic blood pressure, heart rate, level of consciousness, body temperature and supplemental oxygen dependency) used to predict the risk for acute deterioration including sepsis [4,5]. An increasing number of studies have assessed the physiological parameters, vital signs and some scoring systems for severe COVID-19 illness [6,7]. However, there is a lack of knowledge about the predictive value of NEWS2, despite some studies focus on NEWS2 and related scores [3].
To date, limited data exists on the NEWS2 and laboratory parameters in patients with COVID-19. In this study, we aimed to determine prognostic value of NEWS2 and laboratory parameters during the clinical course of COVID-19. Additionally, the correlation between NEWS2 and laboratory parameters at admission (D0), day 3 (D3), day 5 (D5) and day 7 (D7) were evaluated. To our knowledge, this is the first study evaluating both NEWS2 and laboratory parameters on the clinical course of COVID-19 in Turkey.

Materials & methods

Study design & patients
In this retrospective and single-center study, all adult patients (≥18 years old) who were hospitalized for a laboratory confirmed COVID-19, between 11 March and 11 May 2020 were included. SARS-CoV-2 testing was performed using real-time reverse transcription-PCR of samples collected by nasopharyngeal and/or oropharyngeal swabs.

Patients with COVID-19 requiring hospitalization were included in the study. Outpatients and asymptomatic patients were excluded. Also we excluded patients if oropharyngeal or nasopharyngeal swab samples were repeatedly negative for SARS-CoV-2 by reverse transcription-PCR. Our primary outcome was the occurrence of clinical deterioration defined as a composite of ICU admission during hospitalization or in-hospital death.

The criteria for ICU transfer in our hospital were the following parameters (at least one or more); dyspnea and respiratory distress; respiratory rate ≥30/min; oxygen saturation <90% or partial oxygen pressure <60 mmHg despite oxygen support (≥5 l/min); septic shock and/or multiple organ dysfunction.

Data collection
Epidemiological and demographic characteristics, clinical, laboratory, radiological findings and outcomes were collected from medical records. Vital signs including respiratory rate, peripheral capillary oxygen saturation, heart rate, blood pressure, body temperature and consciousness (Glasgow coma scale) were recorded. Laboratory parameters including albumin, C-reactive protein (CRP), procalcitonin, hemoglobin, hematocrit, neutrophil count, lymphocyte count, platelet count, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), urea, ferritin, albumin, fibrinogen, D-dimer, aspartate aminotransferase (AST) and alanin aminotransferase at D0, D3, D5 and D7 were included. The NEWS2 score was calculated at D0, D3, D5 and D7. These parameters were obtained at the same time.

Statistical analysis
Quantitative variables are expressed as mean and standard deviation when they contain continuous and normal distributed data. When the data were not distributed normally, median and interquartile range (IQR) were used. When they contained categorical data, they were expressed as a percentage (%) and frequency (n). Comparison of qualitative variables was performed by Pearson's Chi-square test. The normal distribution questioning the necessity of using the parametric test was examined by Kolmogrov–Smirnov, Shapiro–Wilk, Kurtosis–Skewness tests and box plot distribution. When normally distributed data could not be determined, nonparametric tests and spearman correlation were used. Kruskal–Wallis test was used for the analysis of continuous and more than two independent nonparametric groups (Bonferroni correction was used when necessary) and Mann–Whitney test was used for post hoc analysis. To evaluate the factors in prognosis which were admission ICU and in-hospital death, univariate logistic regression analysis was performed. Afterward, these dependent groups were handled one by one, receiver operating characteristic (ROC) curves were drawn and cut-off values, sensitivity and specificity and area under the curve (AUC) were demonstrated. To predict clinical deterioration, the prognostic accuracy of NEWS2 and laboratory parameters at D0, D3, D5 and D7 was evaluated by ROC analyses.

- NEWS2 and laboratory parameters at D0;
- NEWS2 and laboratory parameters at D3 after excluding from the analysis patients with clinical deterioration within the first 3 days of hospitalization;
- NEWS2 and laboratory parameters at D5 after excluding from the analysis patients with clinical deterioration within the first 5 days of hospitalization;
- NEWS2 and laboratory parameters at D7 after excluding from the analysis patients with clinical deterioration within the first 7 days of hospitalization.

Additionally, the association of the parameters at admission with the clinical deterioration was evaluated to predict the 3-day, 5-day and 7-day end points by ROC analyses.
The results were evaluated in 95% CI and statistical significance level was defined as \( p < 0.05 \). The analyzes were performed using IBM SPSS-21 (Statistical Package for Social Sciences, IL, USA).

**Results**

**General characteristics**

Overall, 611 patients were included. Of whom, 329 (53.8%) were male, the mean age was 52.53 ± 15.07 years. Seventy-three patients (11.9%) were admitted to the ICU. In-hospital death occurred in 46 (7.5%) patients. Among 73 patients (11.9%) admitted to the ICU, 40 patients (54.8%) died during hospitalization. Clinical deterioration was observed in 79 patients (12.9%) during hospitalization, 36 (5.9%) during the first 3 days, 54 (8.8%) during the first 5 days and 62 (10.1%) during the first week of hospitalization. NEWS2 was calculated at D0, D3, D5 and D7 of hospitalization. Patients were stratified into three risk groups: low risk from zero to four; medium risk from five to six and high risk above seven. Of 611 patients, 505 (82.7%) at D0, 411 (91.9%) at D3, 375 (92.2%) at D5, 284 (93.8%) at D7 had a NEWS2 score < 7. The median length of hospital stay was 8.9 days and 332 patients (54.3%) who did not have fever and did not need oxygen in the last 48–72 h and meet the criteria for home monitoring were discharged within the first 7 days. Demographic characteristics of hospitalized patients with COVID-19 are available in Supplementary Table 1.

**ICU admission or in-hospital mortality**

The parameters associated with admission ICU and in-hospital death at D0, D3, D5 and D7 were NEWS2, lymphocyte count, neutrophil count, platelet count, NLR, PLR, CRP, procalcitonin, D-dimer, troponin, AST, urea, lactate dehydrogenase (LDH) and albumin. The median and IQR values of the laboratory parameters and NEWS2 are represented in Table 1.

**Univariate analysis**

In univariate analysis, among parameters associated with ICU admission or in-hospital death at D0, D3, D5 and D7, best predictors were NEWS2, procalcitonin, NLR and albumin. Additionally, D-dimer (at D0, D3 and D7) and hemoglobin (at D3 and D5) were valuable predictors in univariate analysis (Table 2).

**Correlation**

Laboratory parameters correlated with NEWS2 at D0, D3, D5 and D7 were lymphocyte count, neutrophil count, NLR, PLR, CRP, procalcitonin, ferritin and urea (Figures 1 & 2).

**ROC curves**

ROC curves of NEWS2 at D0, D3, D5 and D7 to predict clinical deterioration are shown in Figure 3. AUC curves at D0, D3, D5 and D7 were 0.726, 0.781, 0.833 and 0.842, respectively (all \( p < 0.001 \)).

ROC curves of procalcitonin at D0, D3, D5 and D7 to predict clinical deterioration are shown in Figure 4. AUC curves at D0, D3, D5 and D7 were 0.824, 0.896, 0.967 and 0.823, respectively (all \( p < 0.001; p < 0.001; p = 0.004 \), respectively).

ROC curves of albumin at D0, D3, D5 and D7 to predict clinical deterioration are shown in Figure 5. AUC curves at D0, D3, D5 and D7 were 0.746, 0.868, 0.887 and 0.896, respectively (all \( p < 0.001 \)).

ROC curves of NLR ratio at D0, D3, D5 and D7 to predict clinical deterioration are shown in Figure 6. AUC curves at D0, D3, D5 and D7 were 0.752, 0.893, 0.939 and 0.911, respectively (all \( p < 0.001 \)).

The combined parameter of procalcitonin, NLR, albumin and NEWS2 at D0, D3, D5 and D7 to predict clinical deterioration yielded an increased AUC of 0.838 (95% CI: 0.702–0.883; \( p < 0.001 \)), 0.947 (95% CI: 0.906–0.988; \( p < 0.001 \)), 0.989 (95% CI: 0.967–1.000; \( p < 0.001 \)) and 0.868 (95% CI: 0.647–1.000; \( p = 0.035 \)), respectively. The sensitivities and specificities of combined use were 70.4 and 88.1 at D0, 95.2 and 82.5 at D3, 83.3 and 98.9 at D5, 66.7 and 97.4% at D7, respectively.

Additionally, we analyzed the association of NEWS2, procalcitonin, albumin and NLR at admission with the end point events at D3, D5 and D7. Albumin was the best predictor for the 3-day end-point. AUC was 0.849 (95% CI: 0.755–0.944), sensitivity of 84.1% and specificity of 72.2% (\( p < 0.001 \)). Procalcitonin was the best predictor for the 5-day and 7-day end points. AUC was 0.835 (95% CI: 0.748–0.821), with a sensitivity of 79.2 and specificity of 77.1% (\( p < 0.001 \)) for the 5-day end-point. AUC was 0.849 (95% CI: 0.773–0.924), sensitivity of 79.3 and specificity of 78.2% (\( p < 0.001 \)).
Table 1. Median and interquartile range values of the parameters.

| Parameters                | D0  | D3  | D5  | D7  |
|---------------------------|-----|-----|-----|-----|
|                           | Prognosis | Prognosis | Prognosis | Prognosis |
| **NEW52**                 | Poor | Good | Poor | Good |
| – IQR                     | 4   | 3   | 3   | 2   |
| – Median                  | 6   | 4   | 5   | 3   |
| – p-value                 | 0.001 | 0.001 | 0.001 | 0.001 |
| **Leukocyte count**       | Poor | Good | Poor | Good |
| – IQR                     | 4020 | 2990 | 6745 | 2628 |
| – Median                  | 6075 | 5930 | 7905 | 5800 |
| – p-value                 | 0.26 | 0.001 | 0.01 | 0.04 |
| **Lymphocyte count**      | Poor | Good | Poor | Good |
| – IQR                     | 538 | 810 | 508 | 750 |
| – Median                  | 1030 | 1390 | 805 | 1420 |
| – p-value                 | 0.001 | 0.001 | 0.001 | 0.001 |
| **Neutrophil count**      | Poor | Good | Poor | Good |
| – IQR                     | 4013 | 2410 | 5830 | 2038 |
| – Median                  | 4645 | 3710 | 6565 | 3505 |
| – p-value                 | 0.001 | 0.001 | 0.001 | 0.001 |
| **Platelet count × 10^7** | Poor | Good | Poor | Good |
| – IQR                     | 83 | 82.75 | 132.5 | 120.75 |
| – Median                  | 175 | 197 | 200.5 | 237 |
| – p-value                 | 0.04 | 0.01 | 0.001 | 0.01 |
| **NLR**                   | Poor | Good | Poor | Good |
| – IQR                     | 4.54 | 2.11 | 8.28 | 1.84 |
| – Median                  | 4.83 | 2.7 | 6.6 | 2.35 |
| – p-value                 | 0.001 | 0.001 | 0.001 | 0.001 |
| **PLR**                   | Poor | Good | Poor | Good |
| – IQR                     | 129.8 | 78.2 | 173.1 | 101.6 |
| – Median                  | 180.3 | 141.5 | 250.8 | 162 |
| – p-value                 | 0.001 | 0.001 | 0.001 | 0.01 |
| **CRP**                   | Poor | Good | Poor | Good |
| – IQR                     | 0.64 | 0.05 | 0.79 | 0.05 |
| – Median                  | 0.19 | 0.04 | 0.45 | 0.04 |
| – p-value                 | 0.001 | 0.001 | 0.001 | 0.001 |
| **Procalcitonin**         | Poor | Good | Poor | Good |
| – IQR                     | 1.06 | 0.64 | 3.82 | 0.76 |
| – Median                  | 0.8 | 0.63 | 1.4 | 0.8 |
| – p-value                 | 0.03 | 0.001 | 0.01 | 0.04 |
| **Ferritin**              | Poor | Good | Poor | Good |
| – IQR                     | 416 | 218 | 840 | 174 |
| – Median                  | 234 | 146 | 583 | 171 |
| – p-value                 | 0.01 | 0.001 | 0.01 | 0.16 |
| **Troponin**              | Poor | Good | Poor | Good |
| – IQR                     | 39 | 4.40 | 29.80 | 3.40 |
| – Median                  | 14.6 | 3.9 | 12.5 | 3.2 |
| – p-value                 | 0.001 | 0.001 | 0.01 | 0.01 |

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CPK: Creatine phosphokinase; CRP: C-reactive protein; D0: Admission; D3: Day-3; D5: Day-5; D7: Day-7; IQR: Interquartile range; LDH: Lactate dehydrogenase; NLR: Neutrophil/lymphocyte ratio; PLR: Platelet/lymphocyte ratio.
Table 1. Median and interquartile range values of the parameters (cont.).

| Parameters | D0 | D3 | D5 | D7 |
|------------|----|----|----|----|
| **Prognosis** | Poor | Good | Poor | Good | Poor | Good | Poor | Good |
| **AST** | | | | | | | | |
| – Mean | 23 | 19 | 41 | 24 | 24 | 21 | 27 | 22 |
| – Median | 36.5 | 30 | 51 | 31 | 48 | 36 | 46.5 | 36 |
| – p-value | 0.001 | 0.001 | 0.001 | 0.04 | | | | |
| **ALT** | | | | | | | | |
| – IQR | 13 | 19 | 34 | 26 | 28 | 32 | 30 | 37 |
| – Median | 22.5 | 23 | 27 | 26 | 30.5 | 32 | 28.5 | 35.5 |
| – p-value | 0.86 | 0.13 | 0.95 | 0.31 | | | | |
| **Creatinine** | | | | | | | | |
| – IQR | 0.52 | 0.30 | 0.80 | 0.25 | 1.14 | 0.25 | 0.97 | 0.20 |
| – Median | 0.98 | 0.72 | 0.86 | 0.7 | 0.9 | 0.68 | 0.9 | 0.7 |
| – p-value | 0.001 | 0.001 | 0.02 | 0.09 | | | | |
| **Urea** | | | | | | | | |
| – IQR | 30 | 12 | 34 | 12 | 46 | 12 | 51 | 13 |
| – Median | 39.4 | 27 | 43.7 | 25 | 43.5 | 24 | 33 | 25.8 |
| – p-value | 0.001 | 0.001 | 0.001 | 0.01 | | | | |
| **LDH** | | | | | | | | |
| – IQR | 197 | 114 | 250 | 137 | 151 | 128 | 196 | 138 |
| – Median | 336 | 262 | 468 | 272 | 513 | 281 | 485 | 289 |
| – p-value | 0.001 | 0.001 | 0.001 | 0.001 | | | | |
| **CPK** | | | | | | | | |
| – IQR | 210 | 124 | 360 | 80 | 263 | 58 | 457 | 55 |
| – Median | 170 | 102 | 181 | 72 | 124.5 | 63 | 161.5 | 57 |
| – p-value | 0.02 | 0.001 | 0.08 | 0.01 | | | | |
| **Albumin** | | | | | | | | |
| – IQR | 8 | 5 | 6 | 5 | 7 | 5 | 9 | 4 |
| – Median | 33 | 37 | 31 | 36.5 | 27.5 | 35 | 30 | 34 |
| – p-value | 0.001 | 0.001 | 0.001 | 0.001 | | | | |
| **Hemoglobin** | | | | | | | | |
| – IQR | 2.4 | 2.0 | 2.5 | 2.2 | 2.0 | 1.9 | 2.7 | 2.0 |
| – Median | 13 | 13 | 11.95 | 12.6 | 11.25 | 12.4 | 11.7 | 12.5 |
| – p-value | 0.43 | 0.01 | 0.01 | 0.01 | | | | |
| **Hematocrit** | | | | | | | | |
| – IQR | 7.1 | 5.1 | 5.7 | 5.2 | 4.8 | 6.0 | 6.1 | 5.8 |
| – Median | 38.9 | 39 | 36.05 | 37.7 | 34.3 | 37.1 | 35.6 | 36.7 |
| – p-value | 0.24 | 0.01 | 0.001 | 0.001 | | | | |

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CPK: Creatine phosphokinase; CRP: C-reactive protein; D0: Admission; D3: Day-3; D5: Day-5; D7: Day-7; IQR: Interquartile range; LDH: Lactate dehydrogenase; NLR: Neutrophil/lymphocyte ratio; PLR: Platelet/lymphocyte ratio.

Discussion
In this study, we presented a detailed analysis of the NEWS2 score and laboratory parameters in hospitalized patients with COVID-19. Our results showed that NEWS2, procalcitonin, NLR and albumin at D0, D3, D5, and D7 were the best predictors for clinical deterioration (ICU admission or in-hospital death). The combined effect of NEWS2, procalcitonin, NLR and albumin were more valuable to predict clinical deterioration. Procalcitonin had the highest odds ratio (OR) for clinical deterioration at D0, D3, D5 and D7 in univariate analysis. ROC analyses showed that NEWS2 at D7, procalcitonin at D5, albumin at D7 and NLR at D5 had highest AUC values. Additionally, we detected a strong correlation between NEWS2 and laboratory parameters including lymphocyte count, neutrophil count, NLR, PLR, CRP, procalcitonin, ferritin and urea at D0, D3, D5 and D7.
Early and accurate discrimination of need for ICU improves the clinical course of COVID-19 and reduce unnecessary use of ICU beds. There are several published studies on the use of NEWS2 in COVID-19 patients [2–4,7–13]. However, most studies evaluate NEWS2 at admission only [11–13]. In the study of Sze et al., they suggested that NEWS2 score was not a valuable tool to predict clinical deterioration in elderly patients with COVID-19 [14]. However, they reported the results of only 17 elderly patients. Kim et al. showed that NEWS2 scores on D0 significantly differed in noncritical and critical patients (2.6 ± 2.6 vs 8.2 ± 3.3; p < 0.001) [9]. In the study of Volff et al. the AUC value of NEWS score to predict ICU admission or death was 0.74, in consistent with our result. However, the AUC values of NEWS2 at D3, D5 and D7 were 0.798, 0.833 and 0.842 whereas NEWS2 at D0 was not accurate (AUC < 0.750) [7]. Similarly, Sixt et al. showed that AUC values of NEWS2 was 0.74 at D0, with a best cutoff of six and was 0.98 at D7, with a best cut off of seven. They reported high sensitivity and specificity at D7 (92 and 97%, respectively) [8].

Due to the physiopathological changes, deterioration in different laboratory parameters occurs while the disease progresses. Therefore, laboratory parameters are commonly used for assessing disease severity. Lagadinou et al. found an association between the severity of COVID-19 and the following laboratory parameters NLR, LDH, D-dimers, CRP, fibrinogen and ferritin [15]. In the study of Xu et al. procalcitonin, CRP and NLR were valuable predictors for COVID-19 mortality. They showed that the AUC from highest to lowest was combined effect >CRP >procalcitonin >NLR, respectively [16]. Liao et al. reported that NLR, thrombocytopenia, prothrombin time and D-dimer were associated with death. They showed that increased NLR (≥9-13) was associated with fivefold increased mortality risk [17]. Similarly, in our study, increased NLR was associated with 1.3-fold at D0, 1.8-fold at D3, 1.8-fold at D5 and 1.3-fold at D7 increased mortality risk in univariate analysis. In a meta-analysis, Elshazli et al. demonstrated that higher levels of leukocyte (OR: 5.21), neutrophil (OR: 6.25), D-dimer (OR: 4.19) and prolonged PT (OR: 2.18) was associated with ICU admission. IL-6 (OR: 13.87), CRP (OR: 7.09), D-dimer (OR: 6.36), and neutrophils (OR: 6.25) had the highest ORs for mortality [18]. In a meta-analysis, Lippi et al. showed that increased procalcitonin values are associated with a nearly fivefold higher risk for need for ICU or use of mechanical ventilation (OR: 4.76; 95% CI: 2.74–8.29) [19]. Xu et al. found that procalcitonin (≥0.10 ng/ml, HR: 12.82), CRP (≥52.14 mg/l, HR: 12.30) and NLR (≥3.59, HR: 8.6) had higher HRs of 12.82, 12.30 and 8.6 for mortality, respectively. Additionally, procalcitonin (≥0.10 ng/ml) and CRP (≥52.14 mg/l), but not NLR exhibited independent increasing risks of mortality, with HRs of 52.68 (95% CI: 1.77–1571.66) and 5.47 (95% CI: 1.04–28.72), respectively [16].

In the study of Shang et al. Spearman’s rank correlation analysis revealed that leukocyte, neutrophil, CRP, procalcitonin and LDH were positively correlated and albumin was negatively correlated with mortality in patients with receiving maintenance hemodialysis. Additionally, they showed that CRP had the highest AUC value (0.895) and the values of AUC of neutrophil, albumin and procalcitonin were 0.813, 0.758, 0.757,
0.743 and 0.728, respectively [20]. In contrast, we found that procalcitonin was the best predictor for clinical deterioration in our study. The optimal cut-off value of procalcitonin at D0, D3, D5 and D7 were 0.065, 0.125, 0.155 and 0.120 ng/ml and the sensitivity and specificity to predict clinical deterioration were 81.1 and 67.9% on D0, 80.6 and 89.3% on D3, 87.5 and 96.7% on D5 and 85.7 and 88.2% on D7, respectively.

Procalcitonin is not well studied for COVID-19 cases. However, some studies suggested that increased procalcitonin levels were found to be associated with the disease severity in patients with COVID-19. A meta-analysis...
showed that severe patients with COVID-19 had increased procalcitonin levels [18,19]. Similarly, we found that procalcitonin was the best prognostic parameter for the clinical deterioration in our study. Elevated procalcitonin levels could be associated with acute secondary bacterial pneumonia or systemic secondary bacterial infection in patients with COVID-19 due to the production and release into the circulation from procalcitonin-producing extrathyroidal tissues [21]. In our study, despite elevated procalcitonin levels, this elevation was limited (the cut-
Figure 3. Receiver operating characteristic curves of National Early Warning Score 2 at D0, D3, D5 and D7 to predict clinical deterioration. Receiver operating characteristic curve and performance value for the best cut off for: (A) NEWS2 at admission using clinical deterioration. (B) NEWS2 at D3 using clinical deterioration. (C) NEWS2 at D5 using clinical deterioration. (D) NEWS2 at D7 using clinical deterioration. AUC: Area under the ROC curve; D3: Day-3; D5: Day-5; D7: Day-7; ROC: Receiver operating characteristic.

off values were less than 0.5 ng/ml). In a previous study by Xu et al., they suggested that a limited increase in procalcitonin levels (cut-off value = 0.1 ng/ml) could be associated with increased IFN-γ [16].

Low-serum albumin levels in studies with COVID-19 patients are suggested to be associated with an increased risk of mortality [22–25]. In consistent with other studies, our results confirm that albumin is a valuable predictor for ICU admission or in-hospital death. Albumin is a negative acute phase reactant produced in the liver, and causes downregulation of the expression of angiotensin-converting enzyme-2 receptors, which play a role in the cell entry mechanism of SARS-CoV-2. Liu et al. reported that albumin was associated with clinical deterioration and significantly higher in patients with the improvement/stabilization than in those with disease progression (36.62 ± 6.60 vs 41.27 ± 4.55 g/l, p = 0.006) [24]. In the study of Aziz et al., mean albumin at D0 was
Figure 4. Receiver operating characteristic curves of procalcitonin at D0, D3, D5 and D7 to predict clinical deterioration. Receiver operating characteristic curve and performance value for the best cutoff for: (A) Procalcitonin at admission using clinical deterioration. (B) Procalcitonin at D3 using clinical deterioration. (C) Procalcitonin at D5 using clinical deterioration. (D) Procalcitonin at D7 using clinical deterioration. AUC: Area under the ROC curve; D3: Day-3; D5: Day-5; D7: Day-7; ROC: Receiver operating characteristic.

3.50 g/dl (CI: 3.26–3.74 g/dl) in the severe group and 4.05 g/dl (CI: 3.82–4.27 g/dl) in the nonsevere group (p < 0.001). They reported that hypoalbuminemia was associated with 12.6-fold increased risk of mortality [25].

An increase in neutrophils and a decrease in lymphocytes have been found in various studies. Some studies have shown that NLR may be an important indicator for the severity of COVID-19 patients. Yan et al. showed that NLR was significantly correlated with all-cause in-hospital mortality (OR: 44.351; 95% CI: 4.627–425.088) [26]. The NLR reflects the balance between the innate and adaptive immune systems [26] and increased NLR levels were found to be associated with clinical deterioration in COVID-19 [15–18,26].

This study has several limitations. First, it was retrospectively conducted in a single center. Second, this study had a small sample size and a control group was not included. The generalizability of our results may be limited. Thus,
we need new large scale studies providing important information to better understand COVID-19 pandemic. Our study has also several strengths. First, we were able to admit all critically ill patients requiring intensive care to the ICU during the first months of pandemic. This prevents a selection bias. Second, longitudinal evaluation of the association between clinical deterioration and the dynamic changes of laboratory parameters was performed, since we regularly monitored laboratory parameters during the clinical course.

Conclusion

This study provides a list of several laboratory parameters correlated with NEWS2 and potential predictors for ICU admission or in-hospital death during the clinical course of COVID-19. NEWS2, procalcitonin, NLR and albumin have a high accuracy to predict clinical outcomes/disease progression in hospitalized patients and should
| Parameter                        | p-value | AUC   | 95% CI       | Cut-off | Sensitivity | Specificity |
|---------------------------------|---------|-------|--------------|---------|-------------|-------------|
| Neutrophil/lymphocyte at D0     | <0.001  | 0.752 | 0.694–0.810  | 40.95   | 64.5        | 77.0        |
| Neutrophil/lymphocyte at D3     | <0.001  | 0.893 | 0.843–0.942  | 38.60   | 86.7        | 81.3        |
| Neutrophil/lymphocyte at D5     | <0.001  | 0.939 | 0.899–0.979  | 58.6    | 79.2        | 94.8        |
| Neutrophil/lymphocyte at D7     | <0.001  | 0.911 | 0.834–0.988  | 58.45   | 81.3        | 95.0        |

Figure 6. Receiver operating characteristic curves of neutrophil/lymphocyte ratio at D0, D3, D5 and D7 to predict clinical deterioration. Receiver operating characteristic curve and performance value for the best cutoff for: (A) Neutrophil/lymphocyte ratio at admission using clinical deterioration. (B) Neutrophil/lymphocyte ratio at D3 using clinical deterioration. (C) Neutrophil/lymphocyte ratio at D5 using clinical deterioration. (D) Neutrophil/lymphocyte ratio at D7 using clinical deterioration.

AUC: Area under the ROC curve; D3: Day-3; D5: Day-5; D7: Day-7; NEWS2: National Early Warning Score 2; ROC: Receiver operating characteristic.

be considered in the clinical decision of ICU admission. In conclusion, dynamic monitoring of NEWS2 and laboratory parameters is vital for improving clinical outcomes.

Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/bmm-2021-0061
Author contributions
G Tuncer proposed the concept, designed the study, wrote the protocol and managed the study. G Tuncer, S Surme, IY Nakir and M Yazla, performed the statistics, interpreted the data and wrote the manuscript. S Surme, A Buyukyazgan, AK Cinar, BC Copur, E Zerdali, G Tuncer, H Balli, IY Nakir, M Yazla, Y Kurekci were involved in collecting the data. MM Sonmez, S S-Yavuz, FPehlivanoglu, GSengoz performed a critical review of the manuscript. All authors provided inputs for revision of the manuscript. S Surme communicated with the journal and addressed comments from reviewers. All authors contributed to data acquisition, data analysis or data interpretation and reviewed and approved the final version.

Acknowledgments
The authors acknowledge all the healthcare professionals who contribute to the care of our patients.

Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Summary points
The parameters associated with admission intensive care unit (ICU) and in-hospital death at (D0), day-3 (D3), day-5 (D5) and day-7 (D7) were National Early Warning Score 2 (NEWS2), lymphocyte count, neutrophil count, platelet count, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), C-reactive protein (CRP), procalcitonin, D-dimer, troponin, aspartate aminotransferase, urea, lactate dehydrogenase and albumin.

Laboratory parameters correlated with NEWS2 at D0, D3, D5 and D7 were lymphocyte count, neutrophil count, NLR, PLR, CRP, procalcitonin, ferritin and urea.

Procalcitonin had the highest odds ratio for clinical deterioration on all days.

Receiver operating characteristic analyses showed that NEWS2 at D7, procalcitonin at D5, albumin at D7 and NLR at D5 had highest area under the curve values.

In univariate analysis, among parameters associated with ICU admission or in-hospital death at D0, D3, D5 and D7, best predictors were NEWS2, procalcitonin, NLR and albumin.

This study provides a list of several laboratory parameters correlated with NEWS2 and potential predictors for ICU admission or in-hospital death during the clinical course of COVID-19.

References
Papers of special note have been highlighted as: ○ of interest; ○○ of considerable interest

1. Grasselli G, Zangrillo A, Zanella A et al. COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 323(16), 1574–1581 (2020).
2. Scott LJ, Redmond NM, Tavaré A, Little H, Srivastava S, Pullyblank A. Association between National Early Warning Scores in primary care and clinical outcomes: an observational study in UK primary and secondary care. Br J Gen Pract. 70(695), 374–380 (2020).
3. Greenhalgh T, Treadwell J, Burnow R. NEWS (or NEWS2) score when assessing possible COVID-19 patients in primary care? Cent. Evid-Based. Med. Nuffield. Dep. Prim. Care. Health. Sci. Univ. Oxf (2020). https://www.cebm.net/covid-19/should-we-use-the-news-or-news2-score-when-assessing-patients-with-possible-covid-19-in-primary-care
4. Royal College of Physicians. National Early Warning Score (NEWS) 2: standardising the assessment of acute-illness severity in the NHS. Updated report of a working party 2017 (2021). https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2
5. Smith GB, Prytherch DR, Meredith P, Schmidt PE, Featherstone PI. The ability of the National Early Warning Score (NEWS) to discriminate patients at risk of early cardiac arrest, unanticipated intensive care unit admission, and death. Resuscitation 84(4), 465–470 (2013).
6. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229), 1054–1062 (2020).
7. Satici C, Demirkol MA, Sargin Altunok E et al. Performance of pneumonia severity index and CURB-65 in predicting 30-day mortality in patients with COVID-19. *Int. J. Infect. Dis.* 98, 84–89 (2020).

8. Volff M, Tonon D, Bourenne J, Simeone P, Velly L. No added value of the modified NEWS score to predict clinical deterioration in COVID-19 patients. *Anesth. Crit. Care Pain Med.* 39(5), 577–578 (2020).

9. Sext T, Moretto F, Devilliers H et al. The usefulness of NEWS2 at day 7 of hospitalization in predicting COVID-19 evolution and as an early endpoint in therapeutic trials. *J. Infect.* 82(2), 282–327 (2020).

- Reveals that National Early Warning Score 2 at day-7 had high sensitivity and specificity for clinical deterioration.

10. Kim EJ, Hong HL. Letter to the Editor: discussion of the article “Prognostic accuracy of the SIRS, qSOFA, and NEWS for early detection of clinical deterioration in SARS-CoV-2 infected patients”. *J. Korean Med. Sci.* 35(30), 274 (2020).

11. Jang JG, Hur J, Hong KS, Lee W, Ahn JH. Prognostic accuracy of the SIRS, qSOFA, and NEWS for early detection of clinical deterioration in SARS-CoV-2 infected patients. *J. Korean Med. Sci.* 35(25), 234 (2020).

12. Myrstad M, Ihle-Hansen H, Tveita AA et al. National Early Warning Score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from Covid-19 – a prospective cohort study. *Scand. J. Trauma Resusc. Emerg. Med.* 28(1), 66 (2020).

13. Goulden R, Hoyle MC, Monis J et al. qSOFA, SIRS and NEWS for predicting inhospital mortality and ICU admission in emergency admissions treated as sepsis. *Emerg. Med. J.* 35(6), 345–349 (2018).

14. See S, Pan D, Williams CML et al. Letter to the Editor: variability but not admission or trends in NEWS2 score predicts clinical outcome in elderly hospitalised patients with COVID-19. *J. Infect.* 82(1), 159–198 (2020).

- States that National Early Warning Score 2 was not a valuable tool to predict clinical deterioration in elderly patients with COVID-19. However, they had a small sample size.

15. Lagadinou M, Salomou EE, Zareifopoulos N, Marangos M, Gogos C, Velissaris D. Prognosis of COVID-19: changes in laboratory parameters. *Infect. Med.* 28(Suppl. 1), 89–95 (2020).

16. Xu JB, Xu C, Zhang RB et al. Associations of procalcitonin, C-reaction protein and neutrophil-to-lymphocyte ratio with mortality in hospitalized COVID-19 patients in China. *Sci. Rep.* 10(1), 15058 (2020).

- Recognizes procalcitonin, C-reactive protein (CRP) and neutrophil/lymphocyte ratio (NLR) as valuable predictors for COVID-19 mortality.

17. Liao D, Zhou F, Luo L et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. *Lancet Haematol.* 7(9), 671–678 (2020).

18. Elshazli RM, Toraib EA, Elgaml A et al. Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: a meta-analysis of 6320 patients. *PLoS ONE* 15(8), e0238160 (2020).

- Demonstrates that higher levels of leukocyte, neutrophil, D-dimer and prolonged PT was associated with intensive care unit admission. IL-6, CRP, D-dimer and neutrophils had the highest odds ratio for mortality.

19. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. *Clin. Chim. Acta* 505, 190–191 (2020).

20. Shang W, Li Y, Li H et al. Correlation between laboratory parameters on admission and outcome of COVID-19 in maintenance hemodialysis patients. *Int. Urol. Nephrol.* 52(1), 165–169 (2020).

- Reveals that leukocyte, neutrophil, CRP, procalcitonin and lactate dehydrogenase were positively correlated and albumin was negatively correlated with mortality in COVID-19 patients with receiving maintenance hemodialysis.

21. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. *Clin. Chem. Lab. Med.* 58(7), 1131–1134 (2020).

22. Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. *Liver. Int.* 40(5), 998–1004 (2020).

23. Ponziani FR, Del Zompo F, Neschi A et al. “Gemelli against COVID-19” group. Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients. *Aliment Pharmacol. Ther.* 52(6), 1060–1068 (2020).

24. Liu W, Tao ZW, Wang L et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. *Chin. Med. J. (Engl.)* 133(9), 1052–1058 (2020).

- Reports that albumin was associated with clinical deterioration and significantly higher in patients with the improvement/stabilization than in those with disease progression.

25. Azia M, Fatima R, Lee-Smith W, Assaly R. The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis. *Crit. Care* 24(1), 255 (2020).

26. Yan X, Li F, Wang X et al. Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: a retrospective cross-sectional study. *J. Med. Virol.* 92(11), 2573–2581 (2020).